Social security funding bill adopted in FranceL’Humanité reported on Wednesday (p.6) that France’s social security funding bill PLFSS has been adopted with 335 votes to 190 in the country’s national assembly.
Patients and doctors question why four Alzheimer’s drugs no longer reimbursedLe Figaro reported on Monday (p.12) that both doctors and patients were questioning why four Alzheimer’s drugs were taken off the reimbursement lists on 1 August.
Novartis signs agreement in search for NASH treatmentThe Swiss pharma Novartis has signed agreement with other pharmas including Pfizer, Allergan and Conatus Pharmaceuticals in the search for a treatment for non-alcoholic fatty liver disease (NASH), reported Les Echos on Tuesday (p.16) (APMHE 60342).
New Humira biosimilar approved in U.S.The U.S. Food and Drug Administration has approved a new Humira biosimilar, developed by Novartis’ Sandoz, Les Echos reports on Friday (p.12).
EMA examines bluebird bio’s drug LentiGlobin for severe sickle cell diseaseLes Echos reports on Friday (p.14) that the European Medicines Agency is examining bluebird bio’s drug LentiGlobin for severe sickle cell disease, the first drug for this disease which is currently treated by blood transfusions and bone marrow transplant in the most severe forms of the disease.
Virocovax targets Zika after developing hepatitis B and C vaccineLes Echos reports on Friday on France's Virocovax (p.22). The company has developed a vaccine for hepatitis B and C and is now targeting the Zika virus. No vaccine currently exists for the latter.
Sanofi makes up for drop in diabetes salesLes Echos reports on Friday (p.34) that Sanofi made up for a continuing decline in the sales of its diabetes drug Lantus, with sales of its dermatitis treatment Dupixent in Q3 (APMHE 60373).
Pfizer lowers full-year revenue forecastLes Echos reported on Wednesday (p.18) that Pfizer has lowered its full-year revenue forecast to $53 million to $53.7 million citing competition from generics, pressure from the Trump administration to cut drug prices and a strong dollar (APMHE 60364).
Pfizer Healthcare HubFrench medical start-ups have until 30 November to apply for the acceleration programme Pfizer Healthcare Hub, Les Echos reports on Friday (p.20).
Nicox to delay Nasdaq listingLes Echos reported on Wednesday (p.30) that French biotech Nicox is delaying its Nasdaq listing due to market volatility. Nicox specialises in ophthalmology (APMHE 60357).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.